secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-046052
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna reports 2024 net loss $127.5M; cash runway into 2027; SPS trial 70% enrolled
--------------------------------------------------------------------------------

- Net loss of $127.5M ($3.33 loss per share) for full year 2024 vs $60.4M loss in 2023.
- Cash, equivalents and marketable securities $286.0M as of Dec 31, 2024; expected runway into 2027.
- FDA aligned on registrational Phase 2 design for KYV-101 in stiff person syndrome; 70% enrolled, topline data 1H 2026.
- Phase 2 interim data in myasthenia gravis and Phase 1 data in lupus nephritis expected in 2H 2025.
- KYV-102 IND filing planned for 2H 2025; management team and board strengthened.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000095017025046052/0000950170-25-046052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000095017025046052/kytx-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-046052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer